RxDoctor Payments Data

Robert Reiss, MD

Nephrology · Encinitas, CANPI 1609876341

Payments from drug & device makers

$3,796in general payments, 2019–2025

Across 130 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$879
  • Novartis$474
  • Travere Therapeutics, Inc.$335
  • Amgen$299
  • Calliditas Therapeutics US Inc.$272
  • Ardelyx, Inc.$181
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,74599%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,796 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$227,336
Medicare patients
459
Services billed
1,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol23$33,983
RayaldeeCalcifediol13$33,302
LokelmaSodium Zirconium Cyclosilicate18$28,017
JardianceEmpagliflozin17$26,826
ClinolipidFat Emulsion/Olive/Soy/Phospho49$18,495
Sevelamer Carbonate18$4,537
Calcitriol149$2,814
ProsolParenteral Amino Acid 20% No.119$2,173
Potassium Citrate ErPotassium Citrate12$1,489
Midodrine Hcl20$1,308
Cinacalcet Hcl13$935
Valsartan24$878
Calcium Acetate13$826
Losartan Potassium55$616
Mycophenolate Mofetil11$523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$879$62,00041 claims
OPKO Pharmaceuticals, LLCRayaldee$41$33,30213 claims
Boehringer IngelheimJardiance$48$26,82617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.

Other nephrology in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →